ArticleInfection and immunity2012
Natural history of inhalation melioidosis in rhesus macaques (Macaca mulatta) and African green monkeys (Chlorocebus aethiops).
Article in Infection and immunity, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- Marmosets as models of infectious diseases.Frontiers in cellular and infection microbiology · 2024Review
- Melioidosis in Cynomolgus Macaques (Comparative medicine · 2022Article
- Efficacy of Co-Trimoxazole against Experimental Melioidosis Acquired by Different Routes of Infection.Antimicrobial agents and chemotherapy · 2022Article
- The Innate Immune Response in the Marmoset during the Acute Pneumonic Disease Caused by Burkholderia pseudomallei.Infection and immunity · 2022Article
- Laboratory Safety: Handling Burkholderia pseudomallei Isolates without a Biosafety Cabinet.Journal of clinical microbiology · 2021Article
- Comparative virulence of three different strains of Burkholderia pseudomallei in an aerosol non-human primate model.PLoS neglected tropical diseases · 2021Article
- Evaluation of four sampling devices for Burkholderia pseudomallei laboratory aerosol studies.PLoS neglected tropical diseases · 2021Article
- One Health Approach of Melioidosis and Gastrointestinal Parasitic Infections fromInfection and drug resistance · 2021Article
- Pathogen to commensal? Longitudinal within-host population dynamics, evolution, and adaptation during a chronic >16-year Burkholderia pseudomallei infection.PLoS pathogens · 2020Article
- Dose-dependant acute or subacute disease caused by Burkholderia pseudomallei strain NCTC 13392 in a BALB/c aerosol model of infection.Journal of applied microbiology · 2019Article
- Characterization of the plasma proteome of nonhuman primates during Ebola virus disease or melioidosis: a host response comparison.Clinical proteomics · 2019Article
- Seroepidemiology ofThe American journal of tropical medicine and hygiene · 2018Article
- Melioidosis in Mexico, Central America, and the Caribbean.Tropical medicine and infectious disease · 2018Article
- Use of Reverse Vaccinology in the Design and Construction of Nanoglycoconjugate Vaccines against Burkholderia pseudomallei.Clinical and vaccine immunology : CVI · 2017Article
- Interaction of non-human primate complement and antibodies with hypermucoviscous Klebsiella pneumoniae.Veterinary research · 2016Article
- Article
- Consensus on the development of vaccines against naturally acquired melioidosis.Emerging infectious diseases · 2015Article
- Generation and characterization of large-particle aerosols using a center flow tangential aerosol generator with a non-human-primate, head-only aerosol chamber.Inhalation toxicology · 2015Article
- Comparative experimental subcutaneous glanders and melioidosis in the common marmoset (Callithrix jacchus).International journal of experimental pathology · 2014Article
- Pathogenesis of percutaneous infection of goats with Burkholderia pseudomallei: clinical, pathologic, and immunological responses in chronic melioidosis.International journal of experimental pathology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Burkholderia pseudomallei, the causative agent of melioidosis, is recognized as a serious health threat due to its involvement in septic and pulmonary infections in areas of endemicity and is recognized by the Centers for Disease Control and Prevention as a category B biothreat agent. An animal model is desirable to evaluate the pathogenesis of melioidosis and medical countermeasures. A model system that represents human melioidosis infections is essential in this process. A group of 10 rhesus macaques (RMs) and 10 African green monkeys (AGMs) was exposed to aerosolized B. pseudomallei 1026b. The first clinical signs were fever developing 24 to 40 h postexposure followed by leukocytosis resulting from a high percentage of neutrophils. Dyspnea manifested 2 to 4 days postexposure. In the AGMs, an increase in interleukin 1β (IL-1β), IL-6, IL-8, gamma interferon (IFN-γ), and tumor necrosis factor alpha (TNF-α) was observed. In the RMs, IL-1β, IL-6, and TNF-α increased. All the RMs and AGMs had various degrees of bronchopneumonia, with inflammation consisting of numerous neutrophils and a moderate number of macrophages. Both the RMs and the AGMs appear to develop a melioidosis infection that closely resembles that seen in acute human melioidosis. However, for an evaluation of medical countermeasures, AGMs appear to be a more appropriate model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.